Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Alzheimer Disease (AD)
Interventions: [18F]GTP1, [18F]PI-2620, [18F]MK-6240; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
Interventions: Pirfenidone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin
Interventions: Bendamustine, Rituximab, Lenalidomide; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Wellesley, Massachusetts • New York, New York

Conditions: Chronic Lymphocytic Leukemia
Interventions: ABT-263; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 6
States / cities: La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions: ABT-199, Rituximab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Chicago, Illinois • New Hyde Park, New York + 1 more

Conditions: Brain Cancer
Interventions: erlotinib, Cytoreductive Surgery; Drug · Procedure
Lead sponsor: Andrew B Lassman, MD; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Interventions: bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin; Biological · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 2
States / cities: San Francisco, California • Vallejo, California

Conditions: Endometrial Cancer
Interventions: Carboplatin/Paclitaxel, Trastuzumab; Drug
Lead sponsor: Yale University; Other
Eligibility: Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 16 more

Conditions: Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions: Posaconazole, ABT-199, Decitabine, Azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 13
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 B estradiol orally, 17 B estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 20 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Jacksonville, Florida • Philadelphia, Pennsylvania

Conditions: Urothelial/Bladder Cancer, Nos
Interventions: Atezolizumab, PGV001, Poly ICLC, Normal saline; Drug · Biological
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

About this Genentech, Inc. sponsor directory page